Back to top
more

Apellis Pharmaceuticals (APLS)

(Real Time Quote from BATS)

$37.70 USD

37.70
17,789

+0.31 (0.83%)

Updated Jul 25, 2024 09:51 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Apellis' (APLS) Q4 Earnings Rise Y/Y, Pegcetacoplan in Focus

by Zacks Equity Research

Apellis' (APLS) bottom line grows year over year in the fourth quarter of 2020 while revenues beat estimates. Main focus of the company is on lead pipeline candidate, pegcetacoplan.

Apellis Pharmaceuticals, Inc. (APLS) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of 293.75% and 35.47%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Apellis' (APLS) Pipeline Candidate Pegcetacoplan Promising

by Zacks Equity Research

Apellis' (APLS) lead pipeline candidate, pegcetacoplan, is a promising one and being developed for several indications.

J&J (JNJ) Acquires Rights for Hemera Biosciences' Gene Therapy

by Zacks Equity Research

Johnson & Johnson's (JNJ) Janssen acquires rights to investigational gene therapy, HMR59, for the treatment of geographic atrophy.

Apellis (APLS) Begins Dosing With Pegcetacoplan in ALS Study

by Zacks Equity Research

Apellis (APLS) and Sobi dose the first patient in the mid-stage MERIDIAN study, which is investigating pegcetacoplan to address adults with sporadic amyotrophic lateral sclerosis.

Apellis' (APLS) Blood Disorder Drug Gets FDA's Priority Tag

by Zacks Equity Research

The FDA accepts Apeliis' (APLS) NDA for pegcetacoplanand and grants priority review for the treatment of paroxysmal nocturnal hemoglobinuria.

Apellis Pharmaceuticals' (APLS) Q3 Loss Wider Than Expected

by Zacks Equity Research

Apellis (APLS) reports a wider-than-expected loss in the third quarter of 2020.

Apellis Submits Pegcetacoplan Applications to FDA and EMA

by Zacks Equity Research

Apellis (APLS) submits an NDA to the FDA and an MAA to the European Medicines Agency for pegcetacoplan for the treatment of paroxysmal nocturnal hemoglobinuria.

Why Is Apellis Pharmaceuticals, Inc. (APLS) Down 3.8% Since Last Earnings Report?

by Zacks Equity Research

Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Apellis Pharmaceuticals (APLS) Stock Might be a Great Pick

by Zacks Equity Research

Apellis Pharmaceuticals (APLS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

Biotech Stock Roundup: Updates From INCY & EXEL, APLS & LIFE Surge on Positive Data

by Zacks Equity Research

A low-key week for the biotech sector, with a few pipeline and regulatory updates.

Apellis' (APLS) PNH Drug Betters Alexion's Soliris in Study

by Zacks Equity Research

Apellis Pharmaceuticals' (APLS) experimental drug pegcetacoplan outperformed Alexion's blockbuster medicine, Soliris, in a phase III head-to-head study. Shares soar.

Are Options Traders Betting on a Big Move in Apellis Pharmaceuticals (APLS) Stock?

by Zacks Equity Research

Investors need to pay close attention to Apellis Pharmaceuticals (APLS) stock based on the movements in the options market lately.

Apellis Pharmaceuticals (APLS) Catches Eye: Stock Jumps 5.2%

by Zacks Equity Research

Apellis Pharmaceuticals (APLS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

    Apellis Pharmaceuticals (APLS) in Focus: Stock Moves 7.1% Higher

    by Zacks Equity Research

    Apellis Pharmaceuticals (APLS) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.